MoonLake ImmunotherapeuticsMEX:MLTXN 30 EV-to-FCF is -6.09 as of Jun. 26, 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 333 Biotechnology companies, MoonLake Immunotherapeutics ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MoonLake Immunotherapeutics's Enterprise Value is MXN24,944.60 Mil.
MoonLake Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4,097.81 Mil. Therefore, MoonLake Immunotherapeutics's EV-to-FCF for today is -6.09.
The historical rank and industry rank for MoonLake Immunotherapeutics's EV-to-FCF or its related term are showing as below:
MEX:MLTXN'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.31 Med: 0 Max: 0
Current: -6.31
MEX:MLTXN's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs MEX:MLTXN: -6.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MoonLake Immunotherapeutics's PE Ratio (TTM) for today is calculated as:
MoonLake Immunotherapeutics's share price for today is MXN305.30.
MoonLake Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-70.915.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MoonLake Immunotherapeutics EV-to-FCF Related Terms
MoonLake Immunotherapeutics EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MLTXN vs AVBP, BCAX, KALV: EV-to-FCF Comparison
For the Biotechnology subindustry, MoonLake Immunotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's EV-to-FCF falls into.
MoonLake Immunotherapeutics's current Enterprise Value is MXN24,944.60 Mil.
MoonLake Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,097.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics (MEX:MLTXN) has a EV-to-FCF of -6.09 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MoonLake Immunotherapeutics and its competitors. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 333 companies in the Biotechnology industry.
Is MoonLake Immunotherapeutics' EV-to-FCF too high?
MoonLake Immunotherapeutics' current EV-to-FCF is -6.09. Based on the distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' EV-to-FCF compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #999999 out of 333 companies for EV-to-FCF. This places MoonLake Immunotherapeutics in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MoonLake Immunotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current EV-to-FCF is -6.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current EV-to-FCF of -6.09. The current EV-to-FCF is -6.09. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current EV-to-FCF is -6.09 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score
Get the complete analysis for MEX:MLTXN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MLTXN has been successfully added to your 
